Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Licenses Eril to Eisai in South Korea
April 9, 2007
- Cook's Zenith AAA Endovascular Graft Reimbursed from April 1
April 9, 2007
- Kissei's MRs Provide Drug Safety Data on the Spot
April 9, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 9, 2007
- Alfresa Aims at 70% Share for Drugs for Narcolepsy with Modafinil
April 9, 2007
- Kobayashi Kako to Distribute Generics in Asian Countries
April 9, 2007
- Rep Track Survey: Anti-Allergy Drugs Enter Pollinosis Season
April 9, 2007
- GENERIC NEWS IN BRIEF
April 9, 2007
- Korosho Issues New Notifications to Accelerate Price Agreements
April 9, 2007
- Pfizer Enhances Sexual Harassment Measures in Response to Law Amendment
April 9, 2007
- Takeda Hired Largest No. of New Graduates in 2007
April 9, 2007
- TOPICS 3 articles
April 9, 2007
- BUSINESS NEWS IN BRIEF
April 9, 2007
- Eisai Aims at 7% Annual Growth in Domestic Market
April 9, 2007
- Zetia, Avastin, Adoair to Be Approved in April
April 9, 2007
- GL on Use of Tamiflu upon Onset of Avian Flu Need No Change: Council
April 9, 2007
- REGULATORY NEWS IN BRIEF
April 9, 2007
- Takeda, CanBas to Jointly Develop Anticancer Treatment
April 9, 2007
- Takeda, LGLS to Collaborate to Develop Anti-Obesity Drugs
April 9, 2007
- Takeda Acquires Full Rights to R-851 from 3M
April 9, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…